Improving the in vivo QTc assay: Nonclinical concentration-QTc modeling for risk assessment.
Saved in:
| Title: | Improving the in vivo QTc assay: Nonclinical concentration-QTc modeling for risk assessment. |
|---|---|
| Authors: | Wisialowski TA; Pfizer, Groton, CT, USA. Electronic address: todd.a.wisialowski@pfizer.com., Ether N; Amgen Inc., Thousand Oaks, CA, USA., Foley CM; AbbVie, North Chicago, IL, USA., Kleiman R; Clario, Philadelphia, PA, USA., Koshman Y; AbbVie, North Chicago, IL, USA., Leishman D; Eli Lilly and Company, Indianapolis, IN, USA., Martel E; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Nichols JV; Labcorp, Madison, WI, USA., Popp J; Labcorp, Madison, WI, USA., Rajamani S; Johnson & Johnson Innovative Medicine, CA, USA., Riley S; Pfizer, Groton, CT, USA., Rossman EI; GSK, Collegeville, PA, USA., Vargas HM; Amgen Inc., Thousand Oaks, CA, USA. |
| Source: | Journal of pharmacological and toxicological methods [J Pharmacol Toxicol Methods] 2024 Jul-Aug; Vol. 128, pp. 107515. Date of Electronic Publication: 2024 May 20. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 9206091 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-488X (Electronic) Linking ISSN: 10568719 NLM ISO Abbreviation: J Pharmacol Toxicol Methods Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1873-488X |
|---|---|
| DOI: | 10.1016/j.vascn.2024.107515 |
